Takeda Oncology
Laura Koppes is an experienced professional in the biopharmaceutical industry, currently serving as a Senior CMC Project Manager at Takeda Oncology since November 2022. Laura has held various roles at Takeda since November 2017, progressing from Associate CMC Project Manager in Cell Therapies to CMC Project Manager, focusing on program strategies and execution across cross-functional teams. Prior experience includes a Biochemistry Research Associate role at Momenta Pharmaceuticals, where Laura conducted proteomic studies, and a Compound Management Associate position at Novartis. Earlier in Laura's career, responsibilities included laboratory studies and data analysis as an Associate Scientist at QPS, LLC, and customer service roles at Rensselaer Polytechnic Institute. Laura Koppes holds a Master's degree in Biotechnology from Northeastern University and a Bachelor's degree in Chemistry from Rensselaer Polytechnic Institute.
This person is not in any teams
This person is not in any offices
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.